SPPAM
IONS icon

Summit Partners Public Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Summit Partners Public Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-450,000
Closed -$33.8M – 190
2026
Q1 		$33.8M Buy
450,000
+150,000
+50% +$11.8M 0.91% 36
2025
Q4 		$23.7M Buy
+300,000
New +$22.6M 0.49% 67

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Summit Partners Public Asset Management's IONS Position: Q2 2026 in Review

Summit Partners Public Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 44% in Q2 2026, selling an estimated $46.4M and leaving 787,263 shares worth $62.4M. The position accounts for 1.1% of the portfolio, ranked #23.

Summit Partners Public Asset Management first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $116M in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Summit Partners Public Asset Management held 787,263 shares of Ionis Pharmaceuticals worth $62.4M as of Q2 2026.
  • Summit Partners Public Asset Management sold 616,770 Ionis Pharmaceuticals shares in Q2 2026, an estimated $46.4M.
  • Ionis Pharmaceuticals made up 1.1% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #23 holding.
  • Summit Partners Public Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Summit Partners Public Asset Management's Ionis Pharmaceuticals position peaked at $116M in Q4 2025.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.